세계의 폰빌레브란트병 시장 보고서(2025년)

Von Willebrand disease (VWD) is a genetic bleeding disorder caused by a deficiency or dysfunction of von Willebrand factor (VWF), a protein that plays a crucial role in blood clotting. The severity of the disorder depends on the amount and functionality of von Willebrand factor in the blood.

The main types of von Willebrand disease include type 1, type 2, and type 3. Type 1 is a mild form of the disorder, where individuals have lower-than-normal levels of von Willebrand factor, leading to difficulties in proper blood clotting. The drugs used to manage VWD include antihemophilic factor, coagulation factor VIII complex, von Willebrand factor, desmopressin acetate, and others, with severity levels ranging from mild to severe. These treatments are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others. They are used by a variety of end-users, such as hospitals, specialty clinics, homecare providers, and others.

The von willebrand disease market research report is one of a series of new reports from The Business Research Company that provides von willebrand disease market statistics, including von willebrand disease industry global market size, regional shares, competitors with a von willebrand disease market share, detailed von willebrand disease market segments, market trends and opportunities, and any further data you may need to thrive in the von willebrand disease industry. This von willebrand disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The von willebrand disease market size has grown strongly in recent years. It will grow from $1.74 billion in 2024 to $1.88 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth during the historic period can be attributed to several factors, including increased awareness of rare bleeding disorders, higher diagnosis rates of von Willebrand disease, growth in research funding for blood disorders, improved access to healthcare, and a rising use of prophylactic treatments in hemophilia care.

The von willebrand disease market size is expected to see strong growth in the next few years. It will grow to $2.48 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The projected growth during the forecast period can be attributed to factors such as the increasing development of gene therapies for bleeding disorders, rising investment in biotechnology research, a growing demand for non-invasive diagnostic techniques, the increasing use of digital health tools for disease monitoring, and the expansion of telemedicine services for rare diseases. Key trends for this period include advancements in gene therapy approaches, the integration of artificial intelligence in diagnostics, innovations in non-invasive diagnostic tools, the introduction of novel drug delivery systems, and the development of digital health platforms for patient education.

The increasing prevalence of bleeding disorders is expected to drive the growth of the von Willebrand disease market. Bleeding disorders refer to medical conditions that impair the body's ability to form blood clots, resulting in prolonged or excessive bleeding. The rise in diagnosed cases of bleeding disorders can be attributed to advancements in medical knowledge and diagnostic tools, which have enabled healthcare professionals to detect conditions that previously went unnoticed. Treatments for von Willebrand disease help patients by improving blood clotting, minimizing excessive bleeding, and enhancing their overall quality of life. For example, a report from the United Kingdom Haemophilia Centre Doctors' Organization revealed that new registrations of Hemophilia A in the UK increased from 16 in 2021 to 19 in 2022. This growing awareness and diagnosis of bleeding disorders are contributing to the expansion of the von Willebrand disease market.

Key players in the von Willebrand disease market are focusing on developing innovative treatments, such as von Willebrand factor (VWF) concentrate, to improve treatment effectiveness, reduce bleeding episodes, and enhance patient outcomes. VWF concentrate is a medication used to treat and prevent bleeding in patients with von Willebrand disease, which is caused by a deficiency or dysfunction of the von Willebrand factor. For instance, in April 2024, Octapharma USA Inc., a US-based pharmaceutical company, announced that Wilate, a VWF concentrate, had been approved by the U.S. Food and Drug Administration (FDA). Wilate is a lyophilized powder solution for intravenous injection used for routine prophylaxis to reduce the frequency of bleeding episodes in both adults and children aged six and older. The FDA granted Wilate orphan drug designation, providing it with up to seven years of market exclusivity to encourage the development of treatments for rare diseases.

In January 2024, Takeda Pharmaceutical Company, based in Japan, acquired Shire plc. for $62 billion. This acquisition aims to strengthen Takeda's position in rare diseases, plasma-derived therapies, and hematology, including treatments for von Willebrand disease and other bleeding disorders. Shire plc, a UK-based biotechnology company, focuses on developing therapies for rare diseases, including von Willebrand disease.

Major players in the von willebrand disease market are Pfizer Inc., Bayer AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Mayo Clinic, CSL Behring (a subsidiary of CSL Limited), Cleveland Clinic, Grifols S.A., Kedrion Biopharma Inc., Shanghai RAAS Blood Products Co. Ltd., Biotest AG, Versiti Inc., Fortis Healthcare Limited, LFB S.A., Hualan Biological Engineering Inc., Bio Products Laboratory Ltd. (BPL), Octapharma AG, Sino Biological Inc., Reliance Life Sciences Pvt. Ltd.

North America was the largest region in the von willebrand disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in von willebrand disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the von willebrand disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The von willebrand disease market consists of sales of antifibrinolytic drugs, harmonal therapy, and clotting factor concentrates. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Von Willebrand Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on von willebrand disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for von willebrand disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The von willebrand disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Type 1; Type 2; Type 3
• 2) By Drugs: Antihemophilic Factor; Coagulation Factor VIII Complex; Von Willebrand Factor; Desmopressin Acetate; Other Drugs
• 3) By Severity: Mild; Moderate; Severe
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 5) By End Users: Hospitals; Speciality Clinics; Homecare; Other End Users
• Sub Segments:
• 1) By Type 1: Mild Von Willebrand Disease; Moderate Von Willebrand Disease; Severe Von Willebrand Disease
• 2) By Type 2: Type 2A; Type 2B; Type 2M; Type 2N
• 3) By Type 3: Congenital Type 3; Acquired Type 3
• Companies Mentioned: Pfizer Inc.; Bayer AG; Sanofi S.A.; Takeda Pharmaceutical Company Limited; Novo Nordisk A/S
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Von Willebrand Disease Market Characteristics

3. Von Willebrand Disease Market Trends And Strategies

4. Von Willebrand Disease Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Von Willebrand Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Von Willebrand Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Von Willebrand Disease Market Growth Rate Analysis
• 5.4. Global Von Willebrand Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Von Willebrand Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Von Willebrand Disease Total Addressable Market (TAM)

6. Von Willebrand Disease Market Segmentation

• 6.1. Global Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1
• Type 2
• Type 3
• 6.2. Global Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antihemophilic Factor
• Coagulation Factor VIII Complex
• Von Willebrand Factor
• Desmopressin Acetate
• Other Drugs
• 6.3. Global Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild
• Moderate
• Severe
• 6.4. Global Von Willebrand Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.5. Global Von Willebrand Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Speciality Clinics
• Homecare
• Other End Users
• 6.6. Global Von Willebrand Disease Market, Sub-Segmentation Of Type 1, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Von Willebrand Disease
• Moderate Von Willebrand Disease
• Severe Von Willebrand Disease
• 6.7. Global Von Willebrand Disease Market, Sub-Segmentation Of Type 2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 2A
• Type 2B
• Type 2M
• Type 2N
• 6.8. Global Von Willebrand Disease Market, Sub-Segmentation Of Type 3, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Congenital Type 3
• Acquired Type 3

7. Von Willebrand Disease Market Regional And Country Analysis

• 7.1. Global Von Willebrand Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Von Willebrand Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Von Willebrand Disease Market

• 8.1. Asia-Pacific Von Willebrand Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Von Willebrand Disease Market

• 9.1. China Von Willebrand Disease Market Overview
• 9.2. China Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Von Willebrand Disease Market

• 10.1. India Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Von Willebrand Disease Market

• 11.1. Japan Von Willebrand Disease Market Overview
• 11.2. Japan Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Von Willebrand Disease Market

• 12.1. Australia Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Von Willebrand Disease Market

• 13.1. Indonesia Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Von Willebrand Disease Market

• 14.1. South Korea Von Willebrand Disease Market Overview
• 14.2. South Korea Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Von Willebrand Disease Market

• 15.1. Western Europe Von Willebrand Disease Market Overview
• 15.2. Western Europe Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Von Willebrand Disease Market

• 16.1. UK Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Von Willebrand Disease Market

• 17.1. Germany Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Von Willebrand Disease Market

• 18.1. France Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Von Willebrand Disease Market

• 19.1. Italy Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Von Willebrand Disease Market

• 20.1. Spain Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Von Willebrand Disease Market

• 21.1. Eastern Europe Von Willebrand Disease Market Overview
• 21.2. Eastern Europe Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Von Willebrand Disease Market

• 22.1. Russia Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Von Willebrand Disease Market

• 23.1. North America Von Willebrand Disease Market Overview
• 23.2. North America Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Von Willebrand Disease Market

• 24.1. USA Von Willebrand Disease Market Overview
• 24.2. USA Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Von Willebrand Disease Market

• 25.1. Canada Von Willebrand Disease Market Overview
• 25.2. Canada Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Von Willebrand Disease Market

• 26.1. South America Von Willebrand Disease Market Overview
• 26.2. South America Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Von Willebrand Disease Market

• 27.1. Brazil Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Von Willebrand Disease Market

• 28.1. Middle East Von Willebrand Disease Market Overview
• 28.2. Middle East Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Von Willebrand Disease Market

• 29.1. Africa Von Willebrand Disease Market Overview
• 29.2. Africa Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Von Willebrand Disease Market Competitive Landscape And Company Profiles

• 30.1. Von Willebrand Disease Market Competitive Landscape
• 30.2. Von Willebrand Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

31. Von Willebrand Disease Market Other Major And Innovative Companies

• 31.1. Mayo Clinic
• 31.2. CSL Behring (a subsidiary of CSL Limited)
• 31.3. Cleveland Clinic
• 31.4. Grifols S.A.
• 31.5. Kedrion Biopharma Inc.
• 31.6. Shanghai RAAS Blood Products Co. Ltd.
• 31.7. Biotest AG
• 31.8. Versiti Inc.
• 31.9. Fortis Healthcare Limited
• 31.10. LFB S.A.
• 31.11. Hualan Biological Engineering Inc.
• 31.12. Bio Products Laboratory Ltd. (BPL)
• 31.13. Octapharma AG
• 31.14. Sino Biological Inc.
• 31.15. Reliance Life Sciences Pvt. Ltd.

32. Global Von Willebrand Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Von Willebrand Disease Market

34. Recent Developments In The Von Willebrand Disease Market

35. Von Willebrand Disease Market High Potential Countries, Segments and Strategies

• 35.1 Von Willebrand Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Von Willebrand Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Von Willebrand Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer